Harrow Health (NASDAQ:HROW) saw some unusual options trading activity on Wednesday. Traders bought 750 call options on the company. This represents an increase of 874% compared to the typical volume of 77 call options.
NASDAQ:HROW opened at $5.61 on Thursday. The company has a fifty day moving average of $5.22 and a 200 day moving average of $6.22. Harrow Health has a 52 week low of $4.10 and a 52 week high of $8.99. The company has a quick ratio of 2.62, a current ratio of 2.83 and a debt-to-equity ratio of 0.79. The firm has a market capitalization of $142.48 million, a P/E ratio of 9.20 and a beta of 0.09.
Harrow Health (NASDAQ:HROW) last issued its quarterly earnings data on Wednesday, November 13th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.27). The company had revenue of $12.76 million for the quarter, compared to analysts’ expectations of $13.31 million. Harrow Health had a net margin of 31.32% and a return on equity of 25.96%. As a group, analysts anticipate that Harrow Health will post -0.08 EPS for the current year.
A number of institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC grew its position in shares of Harrow Health by 18.5% in the 2nd quarter. Renaissance Technologies LLC now owns 1,146,506 shares of the company’s stock worth $9,975,000 after buying an additional 178,700 shares during the period. Vanguard Group Inc. grew its holdings in Harrow Health by 0.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,118,280 shares of the company’s stock valued at $9,729,000 after buying an additional 9,112 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Harrow Health by 40.8% in the 2nd quarter. Acadian Asset Management LLC now owns 560,597 shares of the company’s stock valued at $4,878,000 after buying an additional 162,459 shares in the last quarter. BlackRock Inc. grew its holdings in Harrow Health by 273.3% in the 2nd quarter. BlackRock Inc. now owns 430,524 shares of the company’s stock valued at $3,745,000 after buying an additional 315,209 shares in the last quarter. Finally, Cadence Capital Management LLC purchased a new stake in Harrow Health in the 2nd quarter valued at $2,483,000. 36.29% of the stock is currently owned by institutional investors and hedge funds.
A number of research firms recently commented on HROW. ValuEngine upgraded shares of Harrow Health from a “strong sell” rating to a “sell” rating in a report on Thursday, November 14th. Zacks Investment Research lowered shares of Harrow Health from a “hold” rating to a “sell” rating in a report on Wednesday, November 13th. Finally, Lake Street Capital set a $15.00 price target on shares of Harrow Health and gave the company a “buy” rating in a report on Friday, August 16th. Two equities research analysts have rated the stock with a sell rating and two have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $10.83.
Harrow Health Company Profile
Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.
Read More: Understanding the two types of arbitrage
Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.